Bayer's $415 million sale of interventional equipment business to Boston Science

Source: BioValley May 15, 2014 / bioun / -- Bayer has signed a final agreement to divest its intervention device business to Boston Scientific The sale will include Angiojet and jetstream systems, as well as fetch-2 suction catheters for cardiology, radiology and peripheral vascular procedures The deal is expected to be completed in the second half of 2014 at a price of $415 million Through the sale, Bayer's healthcare sector can focus on innovation and growth in radiology and diabetes care, Bayer said in a statement In radiology, Bayer is a global leader in contrast-enhanced imaging diagnostic equipment, contrast agents, and total dose management informatics In diabetes care, Bayer is also a technology leader in blood glucose monitoring systems, blood collection equipment and diabetes management software Through this acquisition, Boston science will expand its portfolio of products for the treatment of peripheral vascular diseases Boston Science said Bayer's involvement will be incorporated into the company's peripheral involvement after the deal is completed Bayer's intervention business generated sales of about $120 million in 2013.